Non-Small Cell Lung Cancer

Category

Dr. Lyudmila Bazhenova, MD & Immuno-Oncology Clinical Investigator Discusses Adverse Events

Dr. Lyudmila Bazhenova, professor of Medicine and thoracic oncologist with the University of California San Diego, and active principal investigator in advanced immunotherapy-based clinical trials, highlights immunotherapy-related adverse events (AEs) for the Oncology...

Vaccitech Oncology Limited Enters Collaboration with Cancer Research UK to Fund a Phase I/IIa Clinical Trial as First-Line NSCLC Therapy

 Vaccitech Ltd announced today, December 18th, 2019, that its strategic collaboration with the Ludwig Institute for Cancer Research (Ludwig), Vaccitech Oncology Limited (VOLT), has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600...

OncLive Peer Exchange Provides Perspective on How the Latest Research from the World Conference for Lung Cancer and the ESMO Annual Meetings Translate to Patient Care and Clinical Practice

Suresh S. Ramalingam, MD, FASCO, Winship Canter Institute of Emery University, leads the discussion on the impact of overall survival data from the FLAURA trial treating advanced non-small cell lung cancer (NSCLC). Panelists include Byoung Chul Cho, MD, PhD, Yonsei...

Therapy Advancements and Biomarker Identifications Leading to Improved Ability to Predict and Enhance Responses To Immunotherapeutic Agents In Non–Small Cell Lung Cancer (NSCLC)

Targeted therapy advancements and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer (NSCLC). Available agents that have...

Positive Study Ongoing Study Data from AMG 510 in Patients with Previous Treated KRAS G12C-Mutated Solid Tumors

Amgen (AMGN) announced new data from its ongoing Phase I clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors. AMG 510 is a first-in-class investigational oral therapy designed to selectively and irreversibly target the...

China Medical University-Led Biomarker Study: KRT17 Spurs Non-Small Cell Lung Cancer

Chinese investigators studied Keratin 17 (KRT17), a 48KDa type I intermediate filament, which is mainly expressed in epithelial basal cells. KRT17 has been shown to be overexpressed in many malignant tumors and play an important role in the occurrence and development...

Giorgio V. Scaglioti Presents the 5 Ps in Changing Translational Research in NSCLC: Future Prospects

A new precision medicine-driven digital infrastructure, collaborative in nature and inclusive of various research centers, new biomarkers, oncology detection strategies, immunotherapies and system biology toolsets—needs to be synchronized and packaged for rapid...

Pin It on Pinterest